Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder - Full Text View

Sponsored by:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00045903

Purpose

This study will evaluate the effectiveness of two cognitive behavioral therapies (CBTs) in treating obsessive compulsive disorder (OCD) in patients who are taking medication but still have residual symptoms.

Condition	Intervention
Obsessive-Compulsive Disorder	Behavioral: Exposure and Ritual Prevention (Cognitive Behavioral Therapy) Behavioral: Stress Management Therapy (Cognitive Behavior Therapy)

MedlinePlus related topics: Anxiety Obsessive-Compulsive Disorder

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title:	CBT Augmentation for SRI Pharmacotherapy in OCD

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:

Obsessive-compulsive symptoms measured at Month 2

Secondary Outcome Measures:

General functioning measured at Month 2

Estimated Enrollment:	136
Study Start Date:	August 2000
Study Completion Date:	January 2007

Detailed Description:

Participants remain on their current OCD medication and are randomly assigned to receive one of two CBTs: exposure and ritual prevention or stress management therapy. Exposure and ritual prevention involves imaginal and in-vivo exposure and requires that participants refrain from ritualizing. Stress management involves relaxation, assertiveness training, and structured problem-solving. Therapy occurs twice per week for 2 months. Participants are assessed verbally by an independent evaluator and are asked to complete self-rating forms. Patients who respond are followed for up to 1 additional year. Participants continue to take the same medication and the same monthly therapy for the first 6 months of follow-up. During the second 6 months of follow-up, participants discontinue therapy but continue taking the same medication.

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Obsessive-Compulsive Disorder (OCD) diagnosis
Currently taking a serotonin reuptake inhibitor (SRI, i.e. clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) for OCD

Exclusion Criteria:

Medical or psychiatric conditions that would make participation in the study hazardous
Intensive cognitive-behavioral therapy while on an adequate dose and duration of an SRI for OCD

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00045903

Locations

United States, New York
New York State Psychiactic Institute, Anxiety Disorders Clinic
New York, New York, United States, 10032
United States, Pennsylvania
University of Pennsylvania Center for the Treatment and Study of Anxiety
Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Investigators

Principal Investigator:	Michael Liebowitz, MD	New York State Psychiatric Institute
Principal Investigator:	Edna Foa, MD	University of Pennsylvania

More Information

Related Info This link exits the ClinicalTrials.gov site

Study ID Numbers:	R01 MH45436, DSIR AT-CT
Study First Received:	September 13, 2002
Last Updated:	May 14, 2008
ClinicalTrials.gov Identifier:	NCT00045903
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):

Cognitive Behavioral Therapy

Study placed in the following topic categories:

Anxiety Disorders
Mental Disorders
Obsessive-Compulsive Disorder

Additional relevant MeSH terms:

Pathologic Processes
Disease

ClinicalTrials.gov processed this record on January 16, 2009